Partnership seeks to unlock treatment for lung disease

Qureight, a life-sciences company which is supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School, announced a multi-year strategic collaboration on lung disease research with pharmaceutical firm AstraZeneca. 

The collaboration allows AstraZeneca to use Qureight’s analytics platform and AI models to accelerate and improve research into multiple lung diseases, offering insight into how patients with complex lung diseases could respond to novel drugs. 

“The multi-year collaboration announced today is an important validation of our technology stack and builds on our existing partnership with AstraZeneca, a leader in respiratory care,” said  Dr Muhunthan Thillai, co-founder and CEO of Qureight, which was founded in Cambridge in 2018. 

“We look forward to working closely with AstraZeneca in analysing data from patients with the fibrotic scarring lung IPF and other complex conditions.”